Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M172,297Revenue $M44,033Net Margin (%)12.9Z-Score3.1
Enterprise Value $M182,521EPS $1.5Operating Margin %14.4F-Score4
P/E(ttm))39.6Cash Flow Per Share $6.3Pre-tax Margin (%)15.5Higher ROA y-yN
Price/Book3.510-y EBITDA Growth Rate %3.1Quick Ratio1.6Cash flow > EarningsY
Price/Sales4.15-y EBITDA Growth Rate %-6.3Current Ratio1.8Lower Leverage y-yN
Price/Cash Flow7.1y-y EBITDA Growth Rate %-9.2ROA % (ttm)5.3Higher Current Ratio y-yN
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)11.6Less Shares Outstanding y-yY
Payout Ratio %92.0Shares Outstanding M2,922ROI % (ttm)6.0Gross Margin Increase y-yN

Gurus Latest Trades with MRK

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKJoel Greenblatt 2014-06-30 Add0.09%$54.83 - $59.62
($57.16)
$ 59.564%Add 3456.04%126,844
MRKGeorge Soros 2014-06-30 Buy 0.04%$54.83 - $59.62
($57.16)
$ 59.564%New holding, 86800 sh.86,800
MRKVanguard Health Care Fund 2014-06-30 Reduce-0.28%$54.83 - $59.62
($57.16)
$ 59.564%Reduce -4.85%33,889,948
MRKDodge & Cox 2014-06-30 Reduce-0.23%$54.83 - $59.62
($57.16)
$ 59.564%Reduce -10.01%35,960,137
MRKJean-Marie Eveillard 2014-06-30 Reduce-0.07%$54.83 - $59.62
($57.16)
$ 59.564%Reduce -21.54%1,755,082
MRKDavid Dreman 2014-06-30 Sold Out -0.02%$54.83 - $59.62
($57.16)
$ 59.564%Sold Out0
MRKJean-Marie Eveillard 2014-03-31 Add0.34%$49.49 - $57.47
($54.09)
$ 59.5610%Add 15820.6%2,236,839
MRKDavid Dreman 2014-03-31 Buy 0.02%$49.49 - $57.47
($54.09)
$ 59.5610%New holding, 4431 sh.4,431
MRKJoel Greenblatt 2014-03-31 Buy $49.49 - $57.47
($54.09)
$ 59.5610%New holding, 3567 sh.3,567
MRKJames Barrow 2014-03-31 Reduce-0.48%$49.49 - $57.47
($54.09)
$ 59.5610%Reduce -22.72%22,739,030
MRKDodge & Cox 2014-03-31 Reduce-0.45%$49.49 - $57.47
($54.09)
$ 59.5610%Reduce -18.11%39,959,196
MRKVanguard Health Care Fund 2014-03-31 Reduce-0.15%$49.49 - $57.47
($54)
$ 59.5610%Reduce -2.58%35,616,848
MRKGeorge Soros 2014-03-31 Sold Out -0.06%$49.49 - $57.47
($54.09)
$ 59.5610%Sold Out0
MRKJohn Hussman 2014-03-31 Sold Out -0.01%$49.49 - $57.47
($54)
$ 59.5610%Sold Out0
MRKGeorge Soros 2013-12-31 Buy 0.06%$45.09 - $50.18
($47.86)
$ 59.5624%New holding, 150000 sh.150,000
MRKRuane Cunniff 2013-12-31 Buy $45.09 - $50.18
($47.86)
$ 59.5624%New holding, 4075 sh.4,075
MRKJean-Marie Eveillard 2013-12-31 Reduce-0.16%$45.09 - $50.18
($47.86)
$ 59.5624%Reduce -98.76%14,050
MRKLeon Cooperman 2013-12-31 Sold Out -0.15%$45.09 - $50.18
($47.86)
$ 59.5624%Sold Out0
MRKCharles Brandes 2013-12-31 Reduce-0.14%$45.09 - $50.18
($47.86)
$ 59.5624%Reduce -8.39%2,476,201
MRKJean-Marie Eveillard 2013-09-30 Reduce-0.16%$46.55 - $48.58
($47.88)
$ 59.5624%Reduce -49.6%1,134,041
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
MRK George Soros 2014-06-3086,80000.04New Buy
MRK Joel Greenblatt 2014-06-30126,84400.09+3456.04%
MRK Ruane Cunniff 2014-06-304,60900+4.54%
MRK James Barrow 2014-06-3022,793,2070.781.8+0.24%
MRK Mario Gabelli 2014-06-30160,3160.010.05
MRK Prem Watsa 2014-06-3012,00000.05
MRK Charles Brandes 2014-06-302,434,5310.081.7-0.68%
MRK Vanguard Health Care Fund 2014-06-3033,889,9481.165.2-4.85%
MRK Dodge & Cox 2014-06-3035,960,1371.232-10.01%
MRK Jean-Marie Eveillard 2014-06-301,755,0820.060.25-21.54%
MRK David Dreman 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FRAZIER KENNETH CChairman, President & CEO 2014-09-10Sell9,814$60.48-1.77view
Schechter Adam HEVP & Pres-Global Human Health 2014-08-25Sell22,000$59.7-0.49view
FRAZIER KENNETH CChairman, President & CEO 2014-08-11Sell10,058$574.23view
AMBROSE ADELE DSr.V-P & Chief Comuns Officer 2014-08-04Sell28,669$56.644.89view
FRAZIER KENNETH CChairman, President & CEO 2014-07-10Sell9,987$58.032.38view
GRADDICK WEIR MIRIAN MExe V-P, HR 2014-07-07Sell180,047$59.160.42view
GRADDICK WEIR MIRIAN MExe V-P, HR 2014-07-07Sell180,047$59.160.42view
Deese Willie AExe V-P & Pres. MMD 2014-06-27Sell72,290$58.261.97view
FRAZIER KENNETH CChairman, President & CEO 2014-06-10Sell9,985$58.062.33view
Schechter Adam HEVP & Pres-Global Human Health 2014-05-14Sell10,527$55.916.26view

Press Releases about MRK :

    Quarterly/Annual Reports about MRK:

      News about MRK:

      Articles On GuruFocus.com
      Reasons Why I Will Bet on Sigma Sep 26 2014 
      The Dogs of the Dow Lost Some Steam In The August Heat, But Maintained Their Lead Sep 16 2014 
      The Dogs of the Dow Lost Some Steam In The August Heat, But Maintained Their Lead Sep 16 2014 
      I Am Sure This Pharma-Company Suits Your Portfolio Aug 28 2014 
      Higher Yielding Stocks With A Cheap EV/EBITDA Ratio And Low Debt Figures Aug 28 2014 
      Legendary Investor Irving Kahn's Top Five Stocks Aug 08 2014 
      UnitedHealth Group Up on Weak Day for the Dow Jul 17 2014 
      U.S. Markets Regain Losses from Last Week Jul 14 2014 
      Abner Herrman Is Increasing Position in the Pharmaceutical Sector Jul 11 2014 
      U.S. Equity Markets Continue to Hit New Highs Jun 15 2014 


      More From Other Websites
      1 year later: Buy stocks booted from the Dow? Sep 30 2014
      Indian Prime Minister courts U.S. CEOs Sep 29 2014
      Business events scheduled for Tuesday Sep 29 2014
      Business events scheduled for Tuesday Sep 29 2014
      Merck & Co., Inc. Stock Still Holding Its Position As A Big-Pharma Leader Sep 29 2014
      Merck Partners with eSSENTIAL Accessibility to offer app for people with disabilities Sep 29 2014
      Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA®... Sep 29 2014
      MSD Announces First Presentation of Early Data on the Investigational Use of Pembrolizumab in... Sep 29 2014
      Merck immunotherapy drug shows promise in bladder cancer Sep 29 2014
      Bristol immune drug shows strong effect in melanoma study Sep 29 2014
      Product Innovations and Geographical Expansion Drive Sustained Merck Consumer Health Business Growth Sep 29 2014
      2:21 am Merck announces first presentation of data on the investigational use of KEYTRUDA in... Sep 29 2014
      Merck drug extends immune system fight to stomach cancer Sep 28 2014
      MSD Announces First Presentation of Data on the Investigational Use of Pembrolizumab in Patients... Sep 28 2014
      Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA® (pembrolizumab)... Sep 28 2014
      Merck drug extends immune system fight to stomach cancer Sep 28 2014
      Bristol immunotherapy gets 6-month U.S. FDA review for melanoma Sep 26 2014
      Bristol immunotherapy gets 6-month U.S. FDA review for melanoma Sep 26 2014
      FMHR Final Trade: MRK, NCR & more Sep 26 2014
      [video] FMHR Final Trade: MRK, NCR & more Sep 26 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK